IRTC (iRhythm Holdings) EBIT: $-13.8 Mil (TTM As of Mar. 2026)


IRTC iRhythm Holdings Inc IRTC
75 GF Score
Price $114.73
GF Value $162.87
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is iRhythm Holdings EBIT?

iRhythm Holdings IRTC +2.01% 75 EBIT is $-13.8 Mil as of Mar. 2026. GuruFocus rates IRTC with a GF Score™ of 75/100 and a GF Value™ of $162.87 (Significantly Undervalued). The stock has 1 warning sign investors should review.

iRhythm Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-11.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-13.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. iRhythm Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was -18.81%. iRhythm Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -21.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. iRhythm Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -0.35%.


iRhythm Holdings  (NAS:IRTC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

iRhythm Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-64.74 * ( 1 - 0% )/( (338.826 + 349.436)/ 2 )
=-64.74/344.131
=-18.81 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1020.042 - 130.341 - ( 583.763 - max(0, 151.89 - 702.765+583.763))
=338.826

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1006.365 - 108.121 - ( 549.62 - max(0, 131.75 - 680.558+549.62))
=349.436

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

iRhythm Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-43.812/( ( (193.426 + max(-16.202, 0)) + (197.028 + max(15.981, 0)) )/ 2 )
=-43.812/( ( 193.426 + 213.009 )/ 2 )
=-43.812/203.2175
=-21.56 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(75.706 + 21.634 + 21.662) - (130.341 + 4.201 + 0.66199999999998)
=-16.202

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(80.863 + 23.8 + 26.275) - (108.121 + 4.056 + 2.78)
=15.981

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

iRhythm Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-13.842/3949.810
=-0.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iRhythm Holdings EBIT Related Terms


iRhythm Holdings EBIT Historical Data

* Premium members only.

The historical data trend for iRhythm Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iRhythm Holdings EBIT Chart

iRhythm Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -99.83 -111.75 -119.01 -99.90 -30.44

iRhythm Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.56 -11.89 -2.65 11.66 -10.95

IRTC vs LIVN, HAE, ITGR: EBIT Comparison

For the Medical Devices subindustry, iRhythm Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iRhythm Holdings EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iRhythm Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where iRhythm Holdings's EV-to-EBIT falls into.


IRTC
75GF Score
iRhythm Holdings Inc IRTC
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iRhythm Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-13.8 Mil mean?
iRhythm Holdings (IRTC) has a EBIT of $-13.8 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on iRhythm Holdings.
Is iRhythm Holdings' EBIT too high?
iRhythm Holdings' current EBIT is $-13.8 Mil. Overall, iRhythm Holdings has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRhythm Holdings' EBIT compare to LIVN and HAE?
iRhythm Holdings' EBIT of $-13.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on iRhythm Holdings. iRhythm Holdings's current EBIT is $-13.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRhythm Holdings stock overvalued right now?
Based on GuruFocus' analysis, iRhythm Holdings (IRTC) is currently considered Significantly Undervalued. The stock's GF Value™ is $162.87, compared to a current price of $114.73 — trading 29.6% below its estimated fair value. The current EBIT is $-13.8 Mil. iRhythm Holdings' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For iRhythm Holdings (IRTC), the current EBIT is $-13.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iRhythm Holdings (IRTC) Overvalued in 2026?

Based on GuruFocus' analysis, iRhythm Holdings stock appears to be undervalued. The current stock price of $114.73 is trading 29.6% below its estimated GF Value™ of $162.87. GuruFocus considers iRhythm Holdings to be Significantly Undervalued.

Key valuation signals for IRTC:

  • EBIT: $-13.8 Mil
  • GF Value™: $162.87 vs. price of $114.73 (29.6% below fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the IRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


iRhythm Holdings Business Description

Other Exchanges 0A7L:UK
Address 699 8th Street, Suite 600, San Francisco, CA, USA, 94103
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
75GF Score

Get the complete analysis for IRTC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$114.73
Price
$162.87
GF Value